Journal Club: Gene-Agnostic Gene Therapy to Preserve Vision
Striatech is pleased to announce its next Journal Club: Gene-Agnostic Gene Therapy to Preserve Vision, which will be held on
Read moreStriatech is pleased to announce its next Journal Club: Gene-Agnostic Gene Therapy to Preserve Vision, which will be held on
Read moreA recent study from Constance Cepko’s group at Harvard Medical School offers an encouraging advance toward therapeutic strategies for Retinitis
Read moreAerska, a newly formed biotechnology company focused on transforming the treatment of neurological diseases, has officially launched with $21 million
Read moreA recent study by Janos Groh and colleagues in Mikael Simons’ group at the Institute of Neuronal Cell Biology, Technical
Read moreStressMarq Biosciences, a market leader and pioneer in the field of fibrilized and oligomeric protein preparations for neurodegenerative disease research,
Read moreRetinal degeneration represents a primary cause of irreversible blindness, with both its onset and severity differing significantly among various conditions.
Read moreStriatech, a leader in preclinical vision research devices and tools, has unveiled its New Non-Aversive Animal Platform for the OptoDrum
Read moreStriatech, a pioneer in non-invasive vision research technologies, will showcase its latest advancements at the FELASA 2025 Congress in Athens,
Read moreA research study has showcased the use of Cellendes’ advanced 3-D Life Hydrogel products in developing an immunocompetent, PDMS-free organ-on-chip
Read moreAt Striatech, advancing the future of ophthalmic research is a central commitment. In partnership with the ARVO Foundation for Eye
Read more